MedTrace Logo

Effects on Glycemic Control of WBF-0031 in Subjects With Abnormal Glucose Tolerance

NCT04490460 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-07-29

No results posted yet for this study

Summary

Evaluation of the safety and effects on glycemic control of medical food formulation WBF-0031 in subjects with abnormal glucose control.

Conditions

  • Abnormal Glucose Tolerance

Interventions

DIETARY_SUPPLEMENT

WBF-0031

Medical food formulation WBF-0031

Sponsors & Collaborators

  • Pendulum Therapeutics

    collaborator INDUSTRY

  • Eden Miller

    lead INDUSTRY

Principal Investigators

  • Eden Miller, D.O. · Diabetes and Obesity Care

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2021-02-01
Completion
2021-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04490460 on ClinicalTrials.gov